Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Skyline Approved to Start China Trials of Gene Therapy for Macular Degeneration

publication date: Oct 19, 2023

Shanghai Skyline Therapeutics, a gene therapy company, was approved to start China clinical trials of SKG0106, an AAV gene therapy aimed at neovascular age-related macular degeneration (nAMD). The candidate includes a proprietary novel recombinant adeno-associated virus (rAAV) capsid and a novel transgene genome encoding anti-VEGF protein. In preclinical studies, it showed potent efficacy by inhibiting neovascular growth, which reduces vascular leakage and retinal edema, slowing the progression of nAMD. Skyline started Phase I/IIa US trials of SLG0106 earlier this year. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital